ARS Pharmaceuticals, Inc (SPRY) Stock Forecast & Price Target
ARS Pharmaceuticals, Inc · NASDAQ
$5.39-0.23 (-4.09%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering ARS Pharmaceuticals, Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $24.00 to $30.00, so the covering firms are broadly aligned. The average target of $27.00 sits 401% above the current $5.39. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.30 next quarter toward $-0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to ARS Pharmaceuticals, Inc.
As of Sep, 2 of 2 firms rate SPRY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SPRY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.30
Range $-0.41 – $-0.14 · 3 analysts · -29% YoY
Next period, 3 analysts expect ARS Pharmaceuticals, Inc to earn $-0.30 a share (range $-0.41 – $-0.14), versus $-0.42 a year earlier. Full-year consensus is $-1.84, growing to $-0.89 the year after.
REVENUE · NEXT QUARTER
$31.2M
Range $28.3M – $39.5M · 3 analysts · +11% YoY
Revenue is expected to reach $31.2M (range $28.3M – $39.5M), +11.1% year-over-year. Full-year consensus is $132.3M, rising to $195.7M next year.
Top analysts covering ARS Pharmaceuticals, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SPRY.
#1
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$30.00+456.6% to target
Overall win rate
38%
+ Follow
#2
JW
Jason Wittes
Roth MKM · Rank #311
Buy
$40.00+642.1% to target
Overall win rate
39%
+ Follow
#3
Roanna Ruiz
SVB Leerink · Rank #388
Buy
$24.00+345.3% to target
Overall win rate
31%
+ Follow
#4
Ryan Deschner
Raymond James
Buy
No targeton SPRY
Coverage
—
+ Follow
#5
KB
Kyle Bauser
Roth Capital
Buy
$30.00+456.6% to target
Coverage
—
+ Follow
SPRY stock forecast FAQ
What is SPRY's average 12-month price target?+
The 2 analysts with a live target average $27.00 for ARS Pharmaceuticals, Inc over the next 12 months, ranging from a $30.00 high to a $24.00 low.
Is SPRY stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SPRY?+
The Street-high target is $30.00 (Cantor Fitzgerald), and the Street-low is $24.00 (Leerink Partners). The average of all 2 active targets is $27.00.
How many Wall Street analysts cover SPRY?+
2 analysts have an active rating on ARS Pharmaceuticals, Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering SPRY?+
Among analysts who currently cover SPRY, Josh Schimmer of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $30.00 target.
What is ARS Pharmaceuticals, Inc's projected EPS for next quarter?+
The consensus estimate is $-0.30 per share (range $-0.41 – $-0.14) across 3 analysts. Full-year EPS is projected at $-1.84, rising to $-0.89 the following year.
How much revenue is ARS Pharmaceuticals, Inc expected to report next quarter?+
Consensus revenue is $31.2M (range $28.3M – $39.5M). Full-year revenue is projected at $132.3M, growing to $195.7M next year.
Have analysts been upgrading or downgrading SPRY lately?+
As of Sep, 2 of 2 firms rate SPRY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SPRY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
